Novel selective quinazoline inhibitors of endothelin converting enzyme-1

Kyunghye Ahn, Andre M. Sisneros, Sarah B. Herman, Sharon M. Pan, Donald Hupe, Chitase Lee, Sham Nikam, Xue Min Cheng, Annette M. Doherty, Richard L. Schroeder, Stephen J. Haleen, Semiko Kaw, Noriaki Emoto, Masashi Yanagisawa

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


PD 069185 is a highly selective and structurally novel inhibitor of endothelin converting enzyme-1 (ECE-1). PD 069185 is a trisubstituted quinazoline with an IC50 value of 0.9 ± 0.1 μM for inhibition of human ECE-1 from the solubilized membrane fraction of CHO cells stably transfected with human ECE-1 cDNA. Kinetic analysis revealed that PD 069185 is best fit with a competitive inhibition model with a K(i) value of 1.1 ± 0.1 μM and binds in a reversible manner. The closely related enzyme, ECE-2, is not inhibited at up to 100 μM PD 069185. In addition, PD 069185 at 200-300 μM has little effect on other metalloproteases, such as neutral endopeptidase 24.11, stromelysin, gelatinase A, and collagenase, showing a high ECE-1 specificity. Data are also presented to show that this series of inhibitors are effective in inhibiting ECE-1 in intact cells and in attenuating the increase in perfusion pressure induced by big ET-1 in isolated rat mesentery. These non-peptidic ECE-1 inhibitors should serve as a valuable tool to study the pathophysiological role of endothelin and the therapeutic potential of ECE-1 inhibitors.

Original languageEnglish (US)
Pages (from-to)184-190
Number of pages7
JournalBiochemical and Biophysical Research Communications
Issue number1
StatePublished - Feb 4 1998


  • Big endothelin
  • Endothelin
  • Endothelin converting enzyme
  • Quinazoline

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Novel selective quinazoline inhibitors of endothelin converting enzyme-1'. Together they form a unique fingerprint.

Cite this